Issues related to adherence in the treatment of depression

Primary Psychiatry

Volumn 14, Issue 6, 2007, Pages 42-46

  Shelton, Richard C ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; GENERIC DRUG; IMIPRAMINE; NEFAZODONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; HYPERACTIVITY; LIVER TOXICITY; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 34250821868     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
2. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163(9):1561-1568.
3. Wang PS, Beck AL, Berglund P, et al. Effects of major depression on moment-in-time work performance. Am J Psychiatry. 2004;161(10):1885-1891.
4. Simon GE, Chisholm D, Treglia M, Bushnell D, and the LIDO Group. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry. 2002;24(5):328-335.
5. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood). 1999;18(5):163-171.
6. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res. 2003;12(1):22-33.
7. Frazer A. Antidepressants. J Clin Psychiatry. 1997;58(suppl 6):9-25.
8. Simon GE, Heiligenstein J, Revicki D, et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Earn Med. 1999;8(4):319-325.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
10. Rush AJ, Fava M, Wisniewski SR, and the STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
11. Trivedi MH, Rush AJ, Wisniewski SR, and the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D; implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
12. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
13. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
14. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;17(6):265-271.
15. Roose SP. Tolerability and patient compliance. J Clin Psychiatry. 1999;60(suppl 17):14-17.
16. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67-85.
17. Akerblad AC, Bengtsson F, von Knorring L, Ekselius L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol. 2006;21(2):117-124.
18. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006;26(3):250-258.
19. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61(7):669-680.
20. Trivedi MH, Fava M, Marangell LB, Osser DN, Shelton RC. Use of treatment algorithms for depression. J Clin Psychiatry. 2006;67(9):1458-1465.
21. Trivedi MH, Kern JK, Baker SM, Altshuler KZ. Computerizing medication algorithms and decision support systems for major psychiatric disorders. J Psychiatr Pract. 2000;6(5):237-246.
22. Trivedi MH, Kern JK, Grannemann BD, Altshuler KZ, Sunderajan P. A computerized clinical decision support system as a means of implementing depression guidelines. Psychiatr Serv. 2004;55(8):879-885.
23. Rasmussen KG, Mueller M, Kellner CH, and the CORE Group. Patterns of psychotropic medication use among patients with severe depression referred for electroconvulsive therapy: data from the Consortium for Research on Electroconvulsive Therapy. J ECT. 2006;22(2):116-123.
24. Ramana R, Paykel ES, Surtees PG, Melzer D, Mehta MA. Medication received by patients with depression following the acute episode: adequacy and relation to outcome. Br J Psychiatry. 1999;174:128-134.
25. Isometsa E, Seppala I, Henriksson M, Kekki P, Lonnqvist J. Inadequate dosaging in general practice of tricyclic vs. other antidepressants for depression. Acta Psychiatr Scand. 1998;98(6):451-454.
26. Suominen KH, Isometsa ET, Henriksson MM, Ostamo AI, Lonnqvist JK. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry. 1998;155(12):1778-1780.
27. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277(4):333-340.
28. Simon GE, Lin EH, Katon W, et al. Outcomes of "inadequate" antidepressant treatment. J Gen Intern Med. 1995;10(12):663-670.
29. Shelton RC, Davidson J, Yonkers KA, et al. The undertreatment of dysthymia. J Clin Psychiatry. 1997;58(2):59-65.
30. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289-2304.
31. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-416.
32. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417-422.
33. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. 1989;46(11):971-982.
34. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47(12):1093-1099.
35. Hollon SD. Does cognitive therapy have an enduring effect? Cognit Ther Res. 2003;27(1):71-75.
36. Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatry. 1997;58(suppl 1):11-14.
37. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67(suppl 4):27-30.
38. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(suppl 4):3-7.
39. Kirmayer LJ. Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. J Clin Psychiatry. 2001;62(suppl 13):22-28.
40. Beals J, Novins DK, Whitesell NR, Spicer P, Mitchell CM, Manson SM. Prevalence of mental disorders and utilization of mental health services in two American Indian reservation populations: mental health disparities in a national context. Am J Psychiatry. 2005;162(9):1723-1732.
41. Beals J, Manson SM, Whitesell NR, Spicer P, Novins DK, Mitchell CM. Prevalence of DSM-IV disorders and attendant help-seeking in 2 American Indian reservation populations. Arch Gen Psychiatry. 2005;62(1):99-108.
42. Mah JT, Wong JY, Lee FJ. Pharmacogenetics: role in modifying drug dosage regimens. Ann Acad Med Singapore. 2000;29(5):628-632.
43. Zhou HH, Liu ZQ. Ethnic differences in drug metabolism. Clin Chem Lab Med. 2000;38(9):899-903.
44. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacology Ther. 2000;38(2):61-68.
45. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194.
46. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med. 1995;25(2):191-201.
47. van Seumeren I. Weight gain and hormone replacement therapy: are women's fears justified? Maturitas. 2000;34(suppl 1):S3-S8.
48. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61(suppl 2):20-25.